CSIMarket
 


Dar Bioscience Inc   (DARE)
Other Ticker:  
 

Dar Bioscience Inc 's Working Capital Ratio

DARE's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 0.85 below Dar Bioscience Inc average.

Within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Working Capital Ratio than Dar Bioscience Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 3216, from total ranking in the second quarter 2023 at 3808.

Explain Working Capital Ratio
How much in Current Assets DARE´s has?
What is the value of DARE´s Current Liabilities?


DARE Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 15.35 % 49.37 % 48.45 % 97 % 43.57 %
Y / Y Current Assets Change -54.74 % -55.61 % -38.28 % -22.17 % 2.74 %
Working Capital Ratio MRQ 0.85 0.9 1.21 1.36 2.17
DARE's Total Ranking # 3216 # 3808 # 2930 # 2950 # 2302
Seq. Current Liabilities Change 6.65 % 1.49 % -23.04 % 38.47 % 38.1 %
Seq. Current Assets Change 0.86 % -24.63 % -31.43 % -13.17 % -1.09 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 407
Healthcare Sector # 830
Overall Market # 3216


Working Capital Ratio Statistics
High Average Low
19.74 4.71 0.48
(Mar 31 2018)   (Mar 31 2014)




Financial Statements
Dar Bioscience Inc 's Current Liabilities $ 26 Millions Visit DARE's Balance sheet
Dar Bioscience Inc 's Current Assets $ 22 Millions Visit DARE's Balance sheet
Source of DARE's Sales Visit DARE's Sales by Geography


Cumulative Dar Bioscience Inc 's Working Capital Ratio

DARE's Working Capital Ratio for the trailling 12 Months

DARE Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 15.35 % 49.37 % 48.45 % 97 % 43.57 %
Y / Y Current Assets TTM Growth -54.74 % -55.61 % -38.28 % -22.17 % 2.74 %
Working Capital Ratio TTM 1.1 1.39 1.81 2.18 2.82
Total Ranking TTM # 2848 # 2591 # 2248 # 2191 # 1702
Seq. Current Liabilities TTM Growth 6.65 % 1.49 % -23.04 % 38.47 % 38.1 %
Seq. Current Assets TTM Growth 0.86 % -24.63 % -31.43 % -13.17 % -1.09 %


On the trailing twelve months basis Due to rise in Current Liabilities in the III Quarter 2023 to $26.34 millions, cumulative Working Capital Ratio decreased to 1.1 below the Dar Bioscience Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 499 other companies have achieved higher Working Capital Ratio than Dar Bioscience Inc . While Working Capital Ratio overall ranking has improved so far to 3099, from total ranking during the twelve months ending second quarter 2023 at 4098.

Explain Working Capital Ratio
How much in Current Assets DARE´s has?
What is the value of DARE´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 500
Healthcare Sector # 1041
Within the Market # 3216


trailing twelve months Working Capital Ratio Statistics
High Average Low
12.24 3.78 1.1
(Jun 30 2018)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Mannkind Corporation  2.34 $ 225.575  Millions$ 96.374  Millions
Entrada Therapeutics Inc   2.32 $ 383.043  Millions$ 165.433  Millions
Lftd Partners Inc   2.30 $ 18.874  Millions$ 8.197  Millions
Conduit Pharmaceuticals Inc   2.27 $ 10.443  Millions$ 4.603  Millions
Oramed Pharmaceuticals Inc   2.25 $ 175.705  Millions$ 78.175  Millions
Mallinckrodt Plc  2.24 $ 1,787.500  Millions$ 799.000  Millions
Acurx Pharmaceuticals inc   2.22 $ 7.158  Millions$ 3.223  Millions
Eli Lilly And Company  2.20 $ 23,007.000  Millions$ 10,475.900  Millions
Renovorx Inc   2.19 $ 3.519  Millions$ 1.605  Millions
Nature s Sunshine Products inc   2.19 $ 160.223  Millions$ 73.312  Millions
Vaxxinity Inc   2.15 $ 46.356  Millions$ 21.561  Millions
Adial Pharmaceuticals Inc   2.15 $ 1.135  Millions$ 0.528  Millions
Avalo Therapeutics Inc   2.11 $ 12.659  Millions$ 6.005  Millions
Amphastar Pharmaceuticals Inc   2.10 $ 543.005  Millions$ 257.963  Millions
Geovax Labs Inc   2.09 $ 14.800  Millions$ 7.082  Millions
Jazz Pharmaceuticals Plc  2.06 $ 3,245.752  Millions$ 1,573.325  Millions
Galectin Therapeutics Inc   2.05 $ 21.611  Millions$ 10.522  Millions
Pieris Pharmaceuticals Inc   2.05 $ 59.089  Millions$ 28.866  Millions
Soligenix inc   2.03 $ 10.972  Millions$ 5.403  Millions
Gri Bio Inc   2.01 $ 4.367  Millions$ 2.177  Millions
Virpax Pharmaceuticals Inc   2.00 $ 13.038  Millions$ 6.533  Millions
Rigel Pharmaceuticals Inc  1.97 $ 95.024  Millions$ 48.273  Millions
Tempest Therapeutics Inc   1.95 $ 12.291  Millions$ 6.305  Millions
Equillium Inc   1.94 $ 53.911  Millions$ 27.771  Millions
Amneal Pharmaceuticals Inc   1.91 $ 1,456.075  Millions$ 760.601  Millions
Evolus Inc   1.90 $ 91.999  Millions$ 48.540  Millions
Petros Pharmaceuticals inc   1.89 $ 24.433  Millions$ 12.934  Millions
Johnson and Johnson  1.88 $ 53,703.000  Millions$ 28,562.000  Millions
Puma Biotechnology Inc   1.86 $ 125.354  Millions$ 67.362  Millions
Elite Pharmaceuticals Inc   1.82 $ 34.750  Millions$ 19.078  Millions

Date modified: 2023-11-12T08:23:12+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com